FDA Delivers Long-Anticipated Guidance on Diversity Action Plans

The FDA has published overdue draft guidance on developing diversity action plans for clinical trials, moving the agency a step closer to the statutory mandate that all phase 3 trials include such plans.
Source: Drug Industry Daily